search-icon
AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Rippling alleges ‘spy’ was paid in Deel espionage case
2
Four Wiz founders surge up global billionaires list with $2.2B each
3
Google’s $32B Wiz deal is just the beginning: Tel Aviv’s startup ecosystem is evolving
4
Meta’s Israeli development center moving to new Tel Aviv headquarters
5
Deel and Rippling corporate espionage case takes a turn as accused ‘spy’ agrees to cooperate
More news Buzzmore

Multiple Sclerosis

2 stories about Multiple Sclerosis
ה מטה הנוכחי של טבע ב ארה"ב

Mylan Cuts Price of Generic Copaxone Offering by 60%

11.07.18|Lilach Baumer
Mylan has achieved a 15%-20% market share in the U.S. since launching its generic version in late 2017 with a monthly price tag of $5,000, compared to Teva's $5,800
default image

Former Teva Executive One Step Closer to Bringing Copaxone Rival to Market

31.10.17|Lilach Baumer
Mapi Pharma announced a successful phase II clinical trial for its Copaxone equivalent GA Depot
ProfilesEngineServlet?at=39&mi=10&pt=18&dpi=1243103233&pai=cTech&dpn=4409&mt=1